Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIG MOVES BEING MADE + INSTITUTIONAL INVESTORS MOVING IN ON RGBP
https://investingbulletin.com/2021/04/regen-biopharma-inc-rgbp-signals-its-ambition-to-go-otc-pink-current-with-recent-8k-filing/
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment of pancreatic cancer for a term of 15- years.
The License IP consists of an antigen specific cancer vaccine in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
Interestingly, the Company has a number of high profile products in its pipeline:
Aplastic Anemia Stem Cell Therapy
HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I/II CLINICAL TRIALS
Breast Cancer – dCellVax – IND #16200
Myelodysplastic Syndrome Gene Silencing – DiffronC
Additionally, The Company (RGBP) has attracted the attention of investment “institutions”, i.e. The Asset Management, LLC has invested over $1.1 million dollars into the company, as seen below in obtained SEC ownership breakdown. LG Capital Funding, LLC, Asset Management now owns a total of 5.3%.
Additionally
On Friday, April 9th, Regen Biopharma, Inc. (RGBP) filed an 8-K outlining its ambitious plan to upload a series of filings that would satisfy the SEC and OTC requirements to bring the company back to reporting status with OTC markets, allowing it to up-list to OTC Pink Current status.
RGBP 8K Filings
Regen Biopharma, Inc. (the “Company”) is in the process of preparing financial statements in order that Company may have such statements audited (in the case of Annual Financial Statements) and reviewed (in the case of Quarterly Financial Statements).
Upon completion of the aforementioned audits and reviews and preparation of the required reports, the Company intends file the following delinquent periodic reports with United States Securities and Exchange Commission:
• Form 10-K for the Fiscal Year ended September 30, 2019
• Form 10-Q for the Quarter ended December 31, 2019
• Form 10-Q for the Quarter ended March 31, 2020
• Form 10-Q for the Quarter ended June 30, 2020
• Form 10-K for the Fiscal Year ended September 30, 2020
• Form 10-Q for the Quarter ended December 31, 2020
It's ALL good now!
Be well and prosper..
According to Barchart's trading history summary for RGBP:
https://www.barchart.com/stocks/quotes/RGBP/price-history/historical
1). RGBP's PPS INCREASED 2,445.5% From 2/1/21 To 4/23/21. Within this time period there were a total of 60 trading days. This translates into RGBP's PPS increasing by an average of 40.7 % per day amortized over this period.
When you look at this in perspective, it clearly points to a massive interest building in RGBP with a corresponding substantial rise in trading volume and PPS with expected pull backs due to high volatility, but nevertheless the overall trend is UPWARD! It is therefore logical that the massive interest in this stock will continue to rise with corresponding rises in the PPS.
Looking at the starting point when the Multi-Billion level breakout trading volume began on 4/8/21, i.e. 3,517,548,288 that represented a 571.43% increase in the PPS over the prior day, i,e, .0021 to .0141, there's no doubt where this is going long term.
The most recent High of 0.0593 hit on 4/12/21 on a Billion level break out volume of 1,896,574,976 nine trading days ago, in contrast to its 52-Week High of 0.08, it's just a matter of time before 0.08 is re-tested again, and surpassed due to the massive interest.
2). It's interesting to note that when a Google search is done on RGBP, Eli Lilly appears with mention of its partnership with RGBP for developing therapeutics to treat various cancers and autoimmune diseases AND that they reserve the right to "License or Buy RGBP's developed Compounds and/or New Drugs." (see 1st link below)
https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5214863-regen-collaborative-agreement-eli-lilly-leads-to-success
https://www.prnewswire.com/news-releases/regen-biopharma-inc-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-and-company-585014641.html
https://www.hvst.com/posts/ongoing-agreement-with-eli-lilly-leads-to-discovery-of-several-new-small-molecule-drugs-wm4T1ZDp
https://www.proactiveinvestors.co.uk/companies/news/127723/regen-biopharma-inc-announced-drug-discovery-agreement-with-eli-lilly-and-company-127723.html
https://www.biospace.com/article/releases/regen-biopharma-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-/
https://www.sdbj.com/news/2016/jun/30/regen-biopharma-inks-deal-eli-lilly-and-co/
3). RGBP holds at least 23 Patents, at least one is presently in the discovery or pre-production phase with Eli Lilly and others with various CROs via RGBP's partnership with Oncology Pharma which is an Intellectual Property (IP) outsourcing pharmaceutical development Company. Just as a NOTE: it needs to be said that not ALL patents for pharmaceutical development make it to production, that should be obvious to most, BUT it only takes ONE (1) to generate BILLIONS in revenue, especially in the Hematology-Oncology Cancer treatment space.
https://patents.google.com/?inventor=David+Koos&sort=new
4). RGBP's Milestone Accomplishments History (includes Patents & Partnerships).
https://seekingalpha.com/symbol/RGBP/ratings/blogs
Keep in mind as previously stated RGBP is partnered with Oncology Pharma for development of its Patents that occurs through Contract Research Organization (CRO) outsourcing which is what Oncology Pharma does. This is how RGBP got partnered with Eli Lilly. Oncology Pharma outsources Intellectual Property Patents for pharmaceutical development and commercialization. Essentially, they're an IP Patent Broker exclusively in the pharmaceutical industry niche market of Hematology-Oncology.
Nothing is going to stop RGBP from moving UP into much higher trading PPS ranges but it's going to take time with Market recovery which is what Insider Financial mentions on the above link. ALL Markets turn around eventually.
Be well and prosper...
Thanks Cy
Very insightful, much appreciated as always.
I have learned much from you.
Have a great weekend
Be well and prosper...
Well said and that was a hard lesson I had to learn with ENZ*Z when I was UP $1.8M @0.92 and didn't take any profit wanting to hold long term and avoid Short Term Capital Gains! That was a major mistake! Then later the Naked Short Selling set in for weeks on end, I finally realized it would continue to drop possibly down to my entry point in free fall so I settled for a much lesser amount but when I sold but still walked away with a substantial profit and will still have to pay Short Term Capital Gains. So NOW I know what to do!
Regarding your last paragraph, this is why I substantially INCREASED my GRST share position heading now toward 7M, to do the very thing you mentioned, and also for reason again, this stock is "off the radar" due to its low to moderate volume and no BIG run ups.
I believe this company is the BEST stock on the OTC, a genuine investment with A LOT going for it!
Thanks for the great summary and support!
Be well and prosper...
Thank you!
Does Anyone Happen To Know...
..when the CEO is going to bring the Filings current to get that STOP SIGN down??
Thanks!
Be well and prosper...
NOW THAT'S A GOOD IDEA!!
Be well and prosper...
AMEN!!
UPWARD & ONWARD!!!
Be well and prosper!!!
Now That's AMAZING!! Whales Moving In!
Whoever that was shelled out over $100,000.00 at that pps!
Smart person!
Be well and prosper...
Well said!
That's EXACTLY what happened to TSNP and keep in mind that TSNP was once in the low penny range, it had ZERO product, ZERO revenue, ZERO contracts and ONLY a "good idea" by ONE person- the CEO who had ZERO employees and no business address. The rest is history!
RGBP is a FAR different story, no comparison even slightly!
Be well and prosper...
Barchart says: STRONG BUY!!!
https://www.barchart.com/stocks/quotes/RGBP/overview
Same thing regarding Oncology Pharma who RGBP has a 15- Year licensing partnership with!
https://www.barchart.com/stocks/quotes/ONPH/overview
How coincidental!
Wonder why that is???
Don't let the Market Makers fool you!
I'm LOADING HEAVILY at these once in a lifetime fortune making discount levels!
Be well and prosper...
A CRO is a Contract Research Organization, and if you would like a description of that, Google it!
Be well and prosper...
WoW Cy!
That post is the best I've ever read!
Well thought out as always!
I was just telling someone the other day regarding the current Market condition with the Naked Short Selling by Hedges-MMs, etc, and that my discernment is they're targeting & punishing High Volume OTC break out stocks with skyrocketing percent gains that are pure speculation, no revenue, no product, etc as if these shouldn't even exist, and fortunately GRST doesn't fit this description which is likely the only reason it hasn't been effected like many others that have experienced substantial drops in their PPS losing 70% to 80% in their share price, but I discern this matter is at the front door of a re-bound.
I feel safe putting money into GRST due to it being a solid company with a solid business plan, a solid CEO with a solid business background for forming and growing highly successful businesses that extends to his family, and it's just a matter of time when it becomes a great revenue generating company.
On another note, I also mention to someone the other day that the Naked Short Selling matter is NOT sustainable long term, for reason 1). it is contrary to the MMs "making a Market" which is their fundamental function; and 2). it can and does lead to "Trading Suppression" where volume critically dries up across the board that has a paralyzing effect, people pull out altogether due to fear, and some stocks even come to a near halt with no Bids Or Asks. I noticed this for a few OTC stocks a couple of weeks ago that typically have moderate "normal" daily trading volume.
I'm also aware that there is a Class Action Lawsuit forthcoming against the SEC for allowing this illegal activity that's contrary to their rules and here'a list of that taken from one of their online forums:
Youtube Video published by the SEC on January 9, 2009 titled: Work at The Securities And Exchange Commission.
Great Idea!
Same here!
This play is about long term organic growth!
IMO, the best bet which is what I'm doing is to ADD to my core position as often as possible especially in the sub-penny range!
Be well and prosper!
Very insightful
Thank you
Be well and prosper...
Thanks for that!
Much appreciated.
Be well and prosper...
That was great!
Apparently you're holding several Million Shares like many are here!
I know of someone with at least 12M.
How about you?
So then if "that's all Oncology Pharma is" then how is it they're trading in the $35-$38/Share range that MANY Big Pharmas trade in?? Please provide a detailed answer to this since you're smarter than most and clearly know it all!
It would of been more forthright, transparent, an honest of you to simply say, "listen bud I don't know what definition you're using to define a Big Pharma so FYI the following is the MOST COMMON definition"...and then provide what YOUR understanding of that is.
Not only this, the answer to that question could vary considerably if it were asked of a dozen or more people, just like it would regarding the definition of ANYTHING for that matter!
Therefore since you seem to know so very much and like to laugh your azz off in ridicule, let's start with YOUR DEFINITION of what a Big Pharma is since very clearly you know so very much.
So enlighten me BIG PHARMA GURU!
I'm certainly not one who claims to know everything AND again that definition can vary considerably, so provide YOUR DEFINITION since I'm the "unenlightened" one.
Hello again Cy!
Great to catch up with you!
Thanks as always for the great post(s), always very informative!
Since we last connected I increased my GRST position to 6M
Still have 6M more to go to catch up with you know who! Hope to raise it to 10M soon!
You've been a major force in my decision to do that combined with all the great DD on this Board!
I also own 3M Shares in R*GBP. Are you holding a position in this stock? f so, or not, what's your take on it seeing they're in partnership with the Big Pharma - Oncology Pharma (trading at $35-$38/Share), with exclusive licensing rights on their mRNA Modulator Patent for treating Pancreatic Cancer, with sub-licensing to other Big-Pharmas, and 5% or 10% Royalties on global sales of their pharmaceutical when it comes to market.
Would appreciate your take on this company given the Market position they are now in.
Thanks!
Be well and prosper...
P.S. what do you perceive the PPS will be at the end of this year for GRST?
Thanks much!
Be well and prosper...
Thanks much!
Be well and prosper...
Thanks!
Sounds good!
Be well and prosper...
Question for ALL GRST Investors...
What's anyone's guess what the PPS will be by the end of this Year, Dec 31, 2021?
0.05; 0.10; 015; 0.25; 0.50; 0.75; 1.00; > 1.00?
Any and all estimates greatly appreciated!
Thanks
Be well and prosper...
So what you're saying is Oncology Pharma which of course is a Big Pharma trading at $35-$38/Share, is knowingly or unknowingly partnered with a "scam" company, is that right??
--- Yes
--- No
RGBP's License to Oncology Pharma
SEC LINK:
https://sec.report/Document/0001607062-21-000077/rgbp040721form8l.htm?__cf_chl_jschl_tk__=db65aaa100f06b4601b11ccc9f65a1fba9e35127-1619126957-0-AVcxvKc-we5PhYJrQxSZJ3zxfOXe4_KOFxhHcEbp0aIUFfbHIel_FiOMMyP4wafsj88fnjpXysHvLLY8lXpRlmKzd6bdZEJvOMGVPL2wxnYZKrf4Ud9GMfo63TCbnRPDGVe4y4qdCps9LT2hV2inDDnmRslwuK_--xqUOu8OzvWfZciFEk6fdzTwJ9pzj8Xn70Ja8ZlzXw0WnZX-rKrWHbD20YCXk7f9slpOpVLVVFTd9IBJI-RirT32Lw-m14NpbdP-xET8A3qpXwlGC5nLyUUDvRUr4K0gG65Q-AXnSaU0X5oBNunml22BltfWP8jwmLQQZuQTD_GCNQQIFJ4dzrHkeJgSNhi3lh_bjuyKccjbfa5vms4UHcr0se61YlC3VUc5EB5s4X4UWNqO_JIJFhIqZOUwNg2KcaEMHGuXjjhXXc4sxwvbmt1XgyLgeR_VeKMQhTFbEbMqCLFJycJ-uDkSj9_hzlUGnCGhc6tYkOffYiNL3SnFbsCbMVjzuw47Bg
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of Pancreatic Cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
As consideration to Regen for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to Regen a nonrefundable fee of $55,000 no later than April 20,2021
(b) pay to Regen royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment.
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”), a subsidiary of Regen Biopharma, Inc., entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of Colon Cancer for a term of fifteen years from April 7, 2021.
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021
(b) pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment.
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
KCL Therapeutics, Inc. is a wholly owned subsidiary of Regen Biopharma, Inc.
Well said!
Couldn't be any clearer!
Upward and Onward!
Be well and prosper...
The EXACT REASON why ANY OTC Stock is a Highly Speculative play, so those who invest should take that for granted, period.
TSN*P had ZERO cash, zero product, zero employees but the CEO, no nothing, and they too were 100% dependent on a merger (Humble), and it happened and the rest is history. Today trading in Dollars and those who were are board with TSN*P many of them today are Millionaires & Multi-Millionaires.
So yeah, big risk = big reward, and for those who understand the RISK they're taking, then that's on them.
AMEN TO THAT!!
It's ALL GOOD NOW!!
Be well and proper...
Posted on Oncology Pharma Today!
"Looks like some are taking advice and using some RGBP profits to start a position here as well."
"ONPH and RGBP will be a two headed monster and both will run like wild in the coming days,weeks, and months. A break of $38 sends us over $40 in a hurry, IMO and there's not many left at $38 now.
"Go ONPH and RGBP"
Then EXPLAIN how it is that RGBP in is Partnership with the Big Pharma- Oncology Pharmafor exclusive licensing it's Patent for commercialization??
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-parabolic-run-on-kls-oncology-pharma-deal/131542/
https://www.otcmarkets.com/filing/html?id=14860710&guid=3hrpUnDRtfTjk3h#EX10_1_HTM
https://www.biospace.com/article/releases/oncology-pharma-inc-addresses-pancreatic-cancer-the-need-for-an-effective-therapy-and-the-potential-of-mrna-technology/
Do Big Pharmas partner with "scam" companies???
So do Insurrectionists!
Yeah right!
IF RGBP is a "scam" like you say, then how is it they're in partnership with a BigPharma- Oncology Pharma currently trading at $36/Share.
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-parabolic-run-on-kls-oncology-pharma-deal/131542/
https://www.otcmarkets.com/filing/html?id=14860710&guid=3hrpUnDRtfTjk3h#EX10_1_HTM
Do Big Pharmas partner with "scam" companies???
Please explain this in detail.
That is CORRECT!!!
RGBP passed through Pre-Clinical a long time ago on their immune modulating cancer therapy patent that operates via mRNA. Upon completion of this Pre-Clinical they immediately turned around and filed an IND. (See #1 & #2 Links).
1).
https://pipelinereview.com/index.php/2016032360757/DNA-RNA-and-Cells/Regen-BioPharma-Inc.-Submits-IND-Application-to-FDA-on-tCellVax-a-Checkpoint-Inhibitor-for-Cancer-Therapy.html
2).
https://www.biospace.com/article/releases/regen-biopharma-completes-preclinical-experimentation-for-its-sirna-nr2f6-checkpoint-inhibitor-/?s=83.
There are many factors involved in getting FDA approval for an IND and it's up to the examiners to grant it which they determine on a case by case basis and are not obligated to do so.
Also, an IND can be opened at any stage of the development process, BUT can NOT advance to Human Subjects in Pre-Clinical without FDA approval.
http://www.impactpharma.com/blog/before-you-file-your-ind/
However RGBP did in fact complete the Pre-Clinical Testing several years ago, again for the above mentioned patent which positioned them for where they are today...in partnership with a Big Pharma for advancing their candidate cancer drug patent onward into production and commercialization however I am not aware of when they completed Phases II-IV for this patent, but apparently they did OR they have been granted a provisional go ahead based on the FDA's Fast Tracking provision for urgent need pharmaceutical applications like what happened with the Covid Vaccine.
No matter how anyone looks at it, RGBP has a Big Pharma partners AND has already licensed out its above mentioned patent for production.
I don't claim to know everything about this company BUT I do know where they are today positoned in the Big Pharma market, which is undeniable!
I hope this helps, but please keep in mind that this company has A LOT in their Patent Pipeline that are presently under development but I am not appraised of what stage of development these are at currently.
Be well and prosper...
This SHOULD be MOVING UP DAILY & CONSISTENTLY!!!
...and THAT's based ALONE on this being a highly likely Buy-Out Candidate already in partnership with a Big Pharma: Oncology Pharma
ALSO like I said previously, IGNORE the present artificial Market Conditions on the OTC based on what the Hedge Funds-MMs are doing behind the scenes. It's totally irrelevant and also it's NOT sustainable long term which I already described in detail.
Fact is they won't be able to prevent this from a sky rocketing run into the Dollar+ Range when the time comes, and that can happen in a single trading session.
But nevertheless this should be rising daily, and IMO by now we should already be trading easily North of $1.00 based alone on their partnership with Oncology Pharma (presently trading at $37.90/Share) with a 15-Year Patent licensing, sub-licensing arrangements to other Big Pharmas via Oncology Pharma, and quarterly royalties about to fall to RGB's their bottom line moving forward!
Like I've said more than once already;a NO BRAINER!!!
What more do you WANT???? Do any of you know of any other Bio-Pharma that fits this description on the OTC?? If so, who?? If this was on NASDAQ that would make sense by far, and it's just a matter of time before than happens.
Hope everyone's loaded to the hilt at this current deep discount price range, if not your going to kick yourself later.
This is NOT A PUMP- it's a plain & simple NO BRAINER based on witnessing first hand scores of prior rising stars like this one being brought to market after filing their IND to engage clinical trials.
Now here's something all of you should be aware of and likely are NOT, but I will educate you...only 5 in 5,000 New Patents for Drug development via filing an IND make it to the pre-clinical testing phase on human subjects. Then subsequently, of those 5, only 1 makes it past pre-clinical then onward to all phase completion preparing for treatment application which is the case with RGBP! FACT! If this was NOT the case they would NOT have been looked at twice by ANY BIG PHARMA!!!
So moving forward let us ALL deal in FACTS!!!...but the vast majority of investors are ignorant of these facts which is no fault of theirs, most just simply don't care to know and that's fine.
If you feel this is a PUMP then by all means DON'T BUY A SINGLE SHARE of RGBP and stand on the side lines as a classic "Lookie-Loo" about to get mowed down by this Bullet Train in the making! But then again, you can always take a position when it hits 0.75.
Don't like it?....Don't buy it!...Move on! Find a better play on NASDAQ or NYSE would be your best bet if you're willing to pay $25-$150/Share. Better yet consider Oncology Pharma currently trading at $38.42 at close of Market today, and that's likely a good idea... I AM!!
If you're among those who do like it and you consider yourself well informed in your decision making, then you may want to consider loading at these levels based on what you can afford, keeping in mind that this is nevertheless a speculative play, but much of the risk has been factored out based on what is factual about RGBP and their Big Pharma PARTNER!!
ONWARD & UPWARD!!
Be well and prosper...
Right! This is the risk that the Naked Short Selling (NSS) Hedge Funds & MMs take. The fundamental purpose of ALL MMs is to create Market for Buyers & Sellers.
With NSS the Market dries up and trade volumes dramatically fall causing the Market to approach crashing, thus investors begin to pull out in masses which then has an amplifying effect on the Market drying up.
Well, this is the EXACT OPPOSITE of MMs creating a "normal" Market, therefore they are defeating their own purpose and doing a disservice the entire OTC.
In short, it is NOT sustainable, therefore Market reversal is inevitable, and I believe that will happen sooner than later with the economy returning to normal, real estate market flourishing, retail business returning to normal, jobs opening up, etc, etc.
So the directive should be to invest while prices are low! This is how fortunes are made in the Stock Market, and for those who don't believe this just ask Warren Buffett.
Be well and prosper...
How is it you "just happened to know some...." etc. LOL!
"some" who is "some?"
How transparent you are with your elementary deception.
Well said and a very common matter. Nothing new or unusual about this across the entire Bio-Pharma industry or any other industry for that matter!
Simply put, not all Patents pan out, to think otherwise would be delusional.
It was just a desperate stab by someone who is clueless.
Be well and prosper...
Prove it Joker!
10-4 Copy that!
100% CORRECT!!!
With the exception of ENZ.. there's NO other Bio-Pharma on the OTC that comes anywhere close to RGBP for the reasons you mentioned AND also for the reasons I mentioned in my previous post.
There are a few rising stars out there but NONE at this stage of market development standing at the front door of a Buy-Out! I'm even willing to go out on a limb on this based on 30+ years as a clinical trials physician involved in scores of U.S. based Big Pharma trials, and that is I wouldn't be surprised IF RGBP gets bought out within a year or less, and IMO that will likely be their current partner, Oncology Pharma (O.P.)
WHY?? RGBP already has a 15-year partnership in place AND their science/biotechnology is a natural fit that could lend itself to further Intellectual Property collaborative development in the cancer therapy space. This single point is bigger than most people could imagine.
Not only this it would be in O.P's best interest from a market strength-commercialization-company growth position to simply own RGBP's entire pipeline of biotechnology that represents a whole new generation of hematology-oncology therapeutics worth billions that are absolutely key to a critical area of healthcare in dire need of breakthroughs in advance drug therapies; A TOTAL NO BRAINER!!!
Besides, why compete with emerging biotechnology worth $$BILLIONS$$ when you can OWN IT and substantially increase your Market Cap in the process? Another NO BRAINER!!!
Listen carefully, the BigPharma Industry is EXTREMELY FIERCE and there are companies known to buy out another just to keep their biotechnoloy from coming to Market! Therefore, it would be in Oncology Pharma's best interest to simply OWN RGBP while they have the opportunity to do so; it doesn't take more than common sense to understand this.
https://patents.justia.com/assignee/regen-biopharma-inc
Disclaimer: All the above is only an opinion BUT it's a qualified one based on my lengthy career in therapeutic development.
Onward and upward from here. Best wishes to all.
Be well and prosper...
Thanks!
I'm Long on this Play! Just opened a position recently and glad I did at the current ridiculously low PPS! Talk about a major gift! If this company was on NASDAQ trading at $5 it would be getting snapped up by millions of shares daily sending its pps into the $10-$15 range AND it would still be getting snapped by millions of shares daily in that range as well!
WHY?? Their extensive portfolio of Patents they have that are destine to transition into their extensive "Clinical Trials Pipeline" AND ALSO what they have center stage with their new class of Cancer Immunotherapy based on mRNA modulation that's a promising treatment for Pancreatic Cancer which is presently the 3rd leading cause of deaths by cancers. By 2030, it's expected to move UP to the 2nd leading cause of all cancer related deaths. Presently there are no cures for pancreatic cancer and chemotherepy is an extremely poor treatment prospect with little or no effect.
Essentially their mRNA new drug class qualifies as "disruptive biotechnology" which is the very reason BigPharmas are interested in partnering with them via licensing and/or buy out, which IMO is bound to happen sooner or later.
Great entry point at current pps! Nearly the same as E*NZC about this time last year. Great time to load massively. I already have with a few Mil Shares, and will average down on any and all dips or artificial drops in the PPS due to MM-Hedge manipulation. They can't do that forever, as it's contrary to "making a market", and soon trading comes to a near stand still or ultra low trading volume like it did last week or the week before.
I'm not going to focus on that however for reason it's a distraction relative to the intrinsic value of RGBP with its multiple Patents, recent licensing to Oncology Pharma that's currently trading at $35/Share, then there's royalities from that partnership that will soon begin falling to RGBP's bottom line, and in addition to that they will receive a percentage of all sub-licensing deals by Oncology Pharma to other Big Pharmas.
Can't miss with this one unlike any I've seen before with the exception of E*NZC although they are at least 6 months to 1 year behind RBGP in their progress.
Pushing forward to build a block of several more Million Shares and now's the time to do that!
The ultimate situation that may come out of this is their current BigPharma partner MIGHT decide to buy them out altogether which IF that happens, it would most likely be going into Phase III Clinical Trials that's for evaluating the clinical efficacy of their drug compared to similar pharmaceuticals on the market although there are NONE in the same class! Phase IV is just a formality that takes place after the drug has already been given a name and is being marketed globally, and primarily is for evaluation of long term performance including risks & benefits. By Phase IV the drug has already been bought out by a BigPharma along the way IF the Patent wasn't with a BigPharma from the Get Go!
This is very likely what's going to happen and I would give that about a near 100% chance for reason they're going to need a BigPharma partner who's cash heavy to underwrite the expense of Clinical Trials as well as the marketing and advertisement which cost Millions by itself.
Cytodyn followed this exact same path when they were on the OTC trading at 0.26 and suddenly shot up to $10 not long after they announced a BigPharma partner to do the very things I mentioned here.
It's very clear & obvious to me that RGBP is going to follow this same path. They need BIG BUCKS with a BigPharma who has the infrastructure and expertise to do all these things and a lot more.
Cytodyne's BigPharma partner performed all the required clinical trials and marketing, which they could of never done on their own, way too expensive and enormous man power requirement on many levels of expertise, including regulatory connections to push things through.
Hope this info helps shed light for everyone here on this Rising Star!
My advice to all is to ignore the naked short selling of the Hedges-MMs behind the scene and take full advantage of what they're doing by building a large position while you can at the current major discount level for reason it's NOT going to last forever. I sense they are beginning to back off about now anyway due to many factors in play coming at them.
Be well and prosper...